The global oral proteins and peptides market size reached US$ 1.57 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 2.67 Billion by 2028, exhibiting a growth rate (CAGR) of 8.60% during 2023-2028. The expanding prevalence of chronic diseases, the rising geriatric population, and the increasing preference for oral drugs among consumers represent some of the key factors driving the market.
Proteins and peptides are natural components of the human body and play essential roles in many biological processes. Due to their complex structure and susceptibility to digestion in the stomach and small intestine, they are usually administered through injections. However, oral proteins and peptides can be taken via the oral path to treat hormonal, gastric, and metabolic disorders. They are designed to overcome these challenges by using specialized formulations that protect the molecules from digestion and allow them to be absorbed through the intestinal wall into the bloodstream. These formulations include enteric coatings, nanoparticles, and other delivery technologies. Oral proteins and peptides are extensively utilized to treat numerous chronic diseases, such as diabetes, cancer, and autoimmune disorders.
Oral Proteins and Peptides Market Trends:
The increasing volume of patients suffering from chronic diseases, such as cancer, diabetes, cardiovascular disorders (CVDs), and acquired immunodeficiency syndrome (AIDs), and the expanding geriatric population represent the key factors driving the oral proteins and peptides market growth. Besides this, shifting preferences and the rising demand for effective oral drugs and technology among the masses are contributing to the market growth. Moreover, the escalating consumer health consciousness and the growing awareness of the numerous benefits associated with the consumption of oral protein and peptide supplements are creating a positive outlook for the market. In addition to this, innovative technological advancements, such as three-dimensional (3D) printing, nanotechnology, and genetic engineering, have enabled manufacturers to produce more advanced and cost-effective product variants, which is acting as another significant growth-inducing factor. Concurrent with this, the extensive collaborative efforts between pharmaceutical companies, significant advancements in the healthcare infrastructure, and rising research and development (R&D) activities are presenting remunerative growth opportunities for the market. Furthermore, the inflating disposable income of consumers, the widespread adoption of protein-rich diets, the surging demand for protein powder, bars, and shakes, and the increasing proliferation of online platforms providing easy product access are aiding in market expansion.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each segment of the global oral proteins and peptides market, along with forecasts at the global, regional, and country levels from 2023-2028. Our report has categorized the market based on drug type and application.
Drug Type Insights:
The report has provided a detailed breakup and analysis of the oral proteins and peptides market based on the drug type. This includes linaclotide, plecanatide, calcitonin, insulin, and octreotide. According to the report, insulin represented the largest segment.
- Gastric and Digestive Disorders
- Bone Diseases
- Hormonal Disorders
A detailed breakup and analysis of the oral proteins and peptides market based on the application has also been provided in the report. This includes gastric and digestive disorders, bone diseases, diabetes, and hormonal disorders. According to the report, diabetes accounted for the largest market share.
- North America
- Asia Pacific
- South Korea
- United Kingdom
- Latin America
- Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for oral proteins and peptides. Some of the factors driving the North America oral proteins and peptides market included the increasing prevalence of chronic diseases, the shifting consumer preference for oral drugs, and innovative product advancements.
The report has also provided a comprehensive analysis of the competitive landscape in the global oral proteins and peptides market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Amryt Pharma Plc, AstraZeneca PLC, Biocon Limited, Novo Nordisk A/S, Oramed Ltd, Proxima Concepts Limited, etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
|Base Year of the Analysis
|Drug Types Covered
||Linaclotide, Plecanatide, Calcitonin, Insulin, Octreotide
||Gastric and Digestive Disorders, Bone Diseases, Diabetes, Hormonal Disorders
|| Asia Pacific, Europe, North America, Latin America, Middle East and Africa
||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
||Amryt Pharma Plc, AstraZeneca PLC, Biocon Limited, Novo Nordisk A/S, Oramed Ltd, Proxima Concepts Limited, etc.
||10% Free Customization
|Report Price and Purchase Option
||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support
||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)
Key Questions Answered in This Report:
- How has the global oral proteins and peptides market performed so far, and how will it perform in the coming years?
- What are the drivers, restraints, and opportunities in the global oral proteins and peptides market?
- What is the impact of each driver, restraint, and opportunity on the global oral proteins and peptides market?
- What are the key regional markets?
- Which countries represent the most attractive oral proteins and peptides market?
- What is the breakup of the market based on the drug type?
- Which is the most attractive drug type in the oral proteins and peptides market?
- What is the breakup of the market based on the application?
- Which is the most attractive application in the oral proteins and peptides market?
- What is the competitive structure of the global oral proteins and peptides market?
- Who are the key players/companies in the global oral proteins and peptides market?
Key Benefits for Stakeholders:
- IMARC’s report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the oral proteins and peptides market from 2017-2028.
- The research study provides the latest information on the market drivers, challenges, and opportunities in the global oral proteins and peptides market.
- The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
- Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the oral proteins and peptides industry and its attractiveness.
- Competitive landscape allows stakeholders to understand their competitive environment and provides an insight into the current positions of key players in the market.